Literature DB >> 9811479

Biodistribution of radiolabeled lipid-DNA complexes and DNA in mice.

R Niven1, R Pearlman, T Wedeking, J Mackeigan, P Noker, L Simpson-Herren, J G Smith.   

Abstract

The tissue biodistribution and expression of [33P]DNA-1-[2-[9-(Z)-octadecenoyloxy]ethyl]]-2-[8](Z)-heptadece nyl]-3 -[hydroxyethyl]imidazolinium chloride (DOTIM):cholesterol complexes and 33P-radiolabeled DNA expressing chloramphenicol acetyl transferase (CAT; 4.7 kB) were studied after intravenous (iv) injection in ICR mice. Mice were injected with 200 microL of complex containing DNA at 3 mg/kg or DNA alone. One group received 8 microCi of radioactivity and were sacrificed at 5 and 20 min, and 1, 2, 4 and 24 h post-dose (n = 4/time point). A second group received the equivalent of 3.9 microCi of radioactivity and were sacrificed at 20 min, and 2 and 24 h for subsequent whole body autoradiographic analysis (WBA; n = 2/time point). The tissue distribution of intact DNA was assessed by Southern blot at 24 h post-dose, whereas the integrity of complexes and DNA incubated in heparinized whole blood was studied separately. In further studies, the time course of expression in lung tissue over a 48-h period was examined, and the relative lung-expression of purified open circular (OC) versus supercoiled (SC) DNA at 24 h was evaluated. Approximately 42% of the radioactivity was found in the lungs 5 min after injection and about half this percentage was found in the liver. By 2 h, only 5% remained in the lungs, but 48% was present in the liver. No other tissue accumulated >5% of the dose throughout the duration of the study. WBA radiograms confirmed the tissue distribution results and highlighted significant accumulation of radioactivity in bone over time. Southern Blot analysis demonstrated intact DNA in many tissues 24 h after dosing. In contrast, the majority of DNA incubated in blood was degraded within 2 h, although the complexes afforded some protection relative to DNA alone. The OC DNA expressed equivalently to SC DNA in lung tissue (OC = 1035 +/- 183 pg; SC = 856 +/- 257 pg/mg soluble protein, n = 6, mean +/- SEM) at 24 h, and detectable levels of CAT were present within 2 h of dosing (21.3 +/- 7.2 pg, n >/= 8, mean +/- SD). The results confirm that DNA-DOTIM:cholesterol complexes are initially deposited in the lungs after iv administration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811479     DOI: 10.1021/js980087a

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  Long term stability of poly((2-dimethylamino)ethyl methacrylate)-based gene delivery systems.

Authors:  J Y Cherng; H Talsma; D J Crommelin; W E Hennink
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  Kinetic modeling of plasmid DNA degradation in rat plasma.

Authors:  B E Houk; G Hochhaus; J A Hughes
Journal:  AAPS PharmSci       Date:  1999

Review 3.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 4.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 5.  Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.

Authors:  Zinnia P Parra-Guillén; Gloria González-Aseguinolaza; Pedro Berraondo; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

Review 6.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

7.  Transfection mediated by pH-sensitive sugar-based gemini surfactants; potential for in vivo gene therapy applications.

Authors:  Luc Wasungu; Marco Scarzello; Gooitzen van Dam; Grietje Molema; Anno Wagenaar; Jan B F N Engberts; Dick Hoekstra
Journal:  J Mol Med (Berl)       Date:  2006-06-08       Impact factor: 4.599

Review 8.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

9.  Cell targeting in anti-cancer gene therapy.

Authors:  Mohd Azmi Mohd Lila; John Shia Kwong Siew; Hayati Zakaria; Suria Mohd Saad; Lim Shen Ni; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2004-01

10.  Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen.

Authors:  Vincent W Bramwell; Jim E Eyles; Satyanarayana Somavarapu; H Oya Alpar
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.